|Bid||0.00 x 1000|
|Ask||0.00 x 1200|
|Day's Range||79.95 - 81.72|
|52 Week Range||68.44 - 84.56|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||37.19|
|Earnings Date||Oct 28, 2021|
|Forward Dividend & Yield||2.60 (3.20%)|
|Ex-Dividend Date||Sep 14, 2021|
|1y Target Est||93.88|
Subscribe to Yahoo Finance Plus to view Fair Value for MRKLearn more
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
Indonesia is "finalising" a deal with Merck & Co to procure its experimental antiviral pills, named molnupiravir, to treat COVID-19 ailments, its health minister said on Monday. Results https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 from a large clinical trial this month showed that the pill, made with Ridgeback Biotherapeutics, cut hospitalisations and deaths by 50%. Merck asked for an emergency use clearance from the United States earlier this month.
KENILWORTH, N.J., October 25, 2021--Merck Announces Positive Top-Line Results from Phase 3 Trials for Once-Daily Oral Combination of Doravirine/Islatravir for Treatment HIV-1 Infection